Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00907998
Recruitment Status : Completed
First Posted : May 25, 2009
Last Update Posted : November 20, 2009
Information provided by:

Brief Summary:
The design of this study will enable an extensive evaluation of safety, tolerability, and PK-PD relationship following 4 weeks of dosing in patients with Coronary heart Disease

Condition or disease Intervention/treatment Phase
Coronary Heart Disease Drug: APL180 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180
Study Start Date : June 2009
Actual Primary Completion Date : October 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: APL180 (first dose level) Drug: APL180
Experimental: APL180 (second dose level) Drug: APL180
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Safety and tolerability of APL180 [ Time Frame: Throughout the study ]

Secondary Outcome Measures :
  1. Pharmacokinetics of APL180 [ Time Frame: Throughout the study ]
  2. Evaluate effects of APL180 biomarkers [ Time Frame: Throughout the study ]
  3. Pharmacokinetic-pharmacodynamic relationship of APL180 [ Time Frame: Throughout the study ]
  4. Effect of APL180 on exploratory biomarkers, [ Time Frame: Throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female CHD or CHD equivalent patients
  • Body mass index (BMI) must be within the range of 20 to 35 kg/m2,
  • Patient must have been on a stable statin therapy for >8 weeks prior to first dose except for the statin intolerant patients.

Exclusion criteria:

  • Pregnancy
  • Significant illness within two weeks prior to dosing.
  • Triglycerides ≥ 500 mg/dl (5.65 mmol/l)
  • Uncontrolled hypertension
  • Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety.
  • Presence of NYHA Class III or IV chronic heart failure
  • MI or angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to do Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00907998

Layout table for location information
United States, Alabama
Pinnacle Research Group
Anniston, Alabama, United States, AL36207
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
United States, Texas
Icon Clinical Research
San Antonio, Texas, United States, 78230
Novartis Investigator Site
Copenhagen, Denmark
Novartis Investigator Site
Mainz, Germany
Novartis Investigator Site
Mannheim, Germany
Novartis Investigator Site
Neuss, Germany
Novartis Investigator Site
Rehovot, Israel
Novartis Investigator Site
Tel Aviv, Israel
Novartis Investigator Site
Zrifin, Israel
Novartis Investigator Site
Amsterdam, Netherlands
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00907998    
Other Study ID Numbers: CAPL180A2210B
EudraCT 2009-010877-19
First Posted: May 25, 2009    Key Record Dates
Last Update Posted: November 20, 2009
Last Verified: November 2009
Keywords provided by Novartis:
Coronary heart disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases